Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Satralizumab in Moderate-to-Severe Thyroid Eye Disease
jRCT2011230041Phase 3Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in Graves Orbitopathy (GO) comparing Satralizumab arm with Placebo arm (2 arms). Primary endpoint: Percentage of participants achieving ≥ 2 mm reduction in proptosis from baseline at Week 24 in the study eye. Started Feb 2024; status: active, not recruiting.
02
Drugs
satralizumab
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on jRCT2011230041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011230041.